ARCHIVES

NCI Advisors Approve $20.5M Program Of Grants, Contracts For Biospecimen Research.

This article is from The Cancer Letter archive.

Vol. 33 No. 26 | July 6, 2007

Download PDF Visit The Full Archive

Related Articles

Market Forces Changing Health Care System, Oncologists Told

June 2, 1995

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show

November 28, 1986

Phase II Study: Proton Therapy Can Have Similar Success Rate, Smaller Level of Risk in Treatment of Hodgkin Lymphoma

July 25, 2014

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Chemo Combinations Tested In Phase III For Lung Cancer

August 31, 2001